PMCB NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

PharmaCyte Biotech Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 0.60 USD
-5.2% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -19.1% below the Trend Line and sits at 2.2% of its 52-week range. The latest completed week returned -5.2%, after a -22.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal; earnings are due in 15d.

Setup score 14 out of 100
Latest Close 0.60 USD 24 Jul 2026
1W Return -5.2% latest completed week
4W Return -22.0% short-term follow-through
12W Return -20.5% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.2% Latest completed week; four-week move -22.0%. Indicator stack 0/30 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.49% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 52/100 conviction; expected move 458.3%. News sentiment 49/100 50 relevant articles in the latest sentiment read. Event risk 15d Next report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -19.1% below the Trend Line and sits at 2.2% of its 52-week range. The latest completed week returned -5.2%, after a -22.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0812-week average 0.10

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.08Current proprietary activity-pressure read.
Buy signals2Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -22.0% over four weeks, -20.5% over 12 weeks, and -37.2% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-5.2%
4W-22.0%
12W-20.5%
26W-36.0%
52W-37.2%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.33Latest activity-pressure read.
Pressure change-169.8%Four-week change in activity pressure.
Leadership-33.39Latest relative-leadership reading.
RS change-54.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 30 Apr 2025 Field coverage 67% Model confidence 58%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength45/100Blend of value, momentum, and quality. Underlying universe rank 56; rank 1 is best.
Value47/100Relative valuation strength. Underlying universe rank 54; rank 1 is best.
Quality46/100Profitability and accounting quality. Underlying universe rank 55; rank 1 is best.
Momentum47/100Medium-term price momentum. Underlying universe rank 54; rank 1 is best.
Growth47/100Revenue and earnings growth. Underlying universe rank 54; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-74.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
17.5%
Cash dividends relative to market value.
Buyback yield
11.4%
Net share repurchases relative to market value.
Shareholder yield
29.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.6x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

PMCB shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 458.3%, and Sharemaestro trend signal inactive.

Conviction52/100
Expected move458.3%
Put/call volume0.00
Pressure100
Speculation2
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment49/100

Weighted news tone is neutral across 50 relevant articles.

6 positive · 38 neutral · 6 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings15dNext report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
Options expected move458.3%Nearest-chain priced movement where available.
52-week drawdown-60.3%Distance below the 52-week high.
13-week volatility7.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+11.6%Week of 17 Apr.
Worst week-16.1%Week of 5 Jun.
Latest week-5.2%Week of 24 Jul.

Shape of recent returns

Strong gains6
Modest gains5
Flat weeks0
Modest losses5
Sharp losses10
Recent vol7.0%13-week weekly-return volatility.
Base vol11.9%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew8.5% / -7.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape15/100

Trend, activity pressure, participation, and risk combine to a 15/100 tape read.

 Indicator analysis29/100

Latest 12-week confirmation: trend 0/12, activity pressure 11/12, relative leadership 0/12.

Activity pressure 0.08; No reversal markers Next-Week ExpectancyNegative 42.49%

Next-week expectancy is negative with a 42.49% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors45/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 5 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Options35/100

PMCB shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 458.3%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 458.3% Sentiment49/100

Weighted news tone is neutral across 50 relevant articles.

PMCB|PharmaCyte Biotech Inc|Price:0.586|Chg%:-0.014 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings15d

Next report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20260.60 USD-5.2%0.74 USD1.50 USD-0.33-33.39556.4KOff
17 Jul 20260.63 USD-9.1%0.75 USD1.52 USD0.04-31.68464.6KOff
10 Jul 20260.70 USD-2.6%0.75 USD1.53 USD0.25-28.91398.0KOff
3 Jul 20260.71 USD-7.1%0.76 USD1.54 USD0.40-26.73358.1KOff
26 Jun 20260.77 USD7.2%0.78 USD1.56 USD0.48-21.55367.5KOff
19 Jun 20260.72 USD-5.7%0.78 USD1.57 USD0.65-30.90567.6KOff
12 Jun 20260.76 USD8.7%0.78 USD1.58 USD0.88-25.85696.1KOff
5 Jun 20260.70 USD-16.1%0.78 USD1.60 USD1.08-31.02556.3KOff
29 May 20260.83 USD3.0%0.78 USD1.62 USD1.16-22.46764.1KOff
22 May 20260.81 USD0.7%0.79 USD1.63 USD0.91-23.411.4MOff
15 May 20260.80 USD6.4%0.79 USD1.65 USD0.56-23.953.8MOff
8 May 20260.76 USD0.1%0.80 USD1.66 USD0.15-29.59444.0KOff
1 May 20260.76 USD4.6%0.81 USD1.67 USD-0.18-26.91389.0KOff
24 Apr 20260.72 USD-0.9%0.82 USD1.69 USD-0.29-30.21519.3KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.